Ohio Admin. Code 5122-40-08 - Monitoring program
(A) Each opioid treatment program
shall
is to
review state's
the drug database as
described in
established and maintained by the
state of Ohio board of pharmacy under section
4729.75 of the Revised Code
(the
Ohio's
prescription drug monitoring program) database
maintained by the state board of pharmacy.
(1) Program physicians, or their designees as
allowed by the Ohio
state of Ohio board of pharmacy,
shall
are to
review a patient's information in the database:
(a) At the patient's intake;
(b) At the initiation of treatment;
(c) After the initial thirty days of
treatment;
(d) When the number of
take home doses is increased;
(e)
Every ninety days;
(f) When a
patient refuses to participate in a drug screen; and,
(g)
After any positive drug test indicating any drug screen inconsistent with the
patient's treatment plan.
(2) The physician, or
their designees
the
physician's designee as allowed by the Ohio
state of Ohio
board of pharmacy, shall
is to review information in the drug database
in order to ensure that the patient is not
seeking prescription medication from multiple sources. The results obtained
from the database shall
are to be maintained with the patient records in
accordance with section
4729.86 of the Revised
Code.
(B) All opioid
treatment programs shall
are to participate in the central registry for dual
enrollment, guest dosing, disaster planning, and administrative efforts.
(3)(4)
Within twenty-four hours of patient admission or discharge, the program
shall
is to
report to the central registry, patient
admission data which shall
is to include:
(4)(5) A patient's
medication and dosage shall
is to be updated
within the central registry system at least once a week for disaster planning
efforts.
(1) The central registry will be administered
by the state authority.
(2) The
central registry shall
will be paid for by the opioid treatment programs
through an annual licensing fee that shall
is to be no more
than the cost of the central registry. The amount of the fee
shall
will be
set by the department on a state fiscal year basis and
shall
will be
announced on or before July first of each year.
(3)
To facilitate
timely access to information in the central registry for dual enrollment
verification purposes, opioid treatment programs will ensure that contact
information for program staff is available to the extent necessary to
reasonably facilitate direct communication between providers.
(a)
Provider identification, including program name, county, and address;
(b) Patient identification, including:
(i) Patient name or initials;
(ii) Sex;
(iii) Month, day, and year of birth; and,
(iv) Race,
(c) The month, day, and year of
admission;
(d) The month, day, and
year of discharge, if applicable;
(e) The type of admission (e.g. initial
admission, transfer from another program, change in treatment service,
etc.);
(f) The type of treatment
provided (e.g. detoxification
withdrawal management or maintenance);
(g) The type of medication
prescribed;
(h) The dose of
medication;
(i) Medicaid
identification, if available; and,
(j)
Patient home address.
(C) Opioid
treatment programs shall
are to check the central registry at least once a day
during normal business hours. Opioid treatment programs
shall
are to
verify that new patients are not enrolled in another program through use of the
central registry and by directly checking with other opioid treatment programs
located within a radius of one hundred statute miles who do not participate in
the central registry.
(1) Before a program
admits a patient for treatment, the program shall
is to:
(a) Notify the patient that it cannot provide
medication assisted treatment to a patient who is simultaneously receiving
medication assisted treatment from another program;
(b) Require the patient to sign a written
statement documenting whether they are currently receiving medication assisted
treatment from another program and retain the statement in the patient record.
If the patient refuses to sign this statement, the program shall not admit the
patient for treatment;
(c) Require
the patient to provide the following information:
(i) Full name and any aliases;
(ii) Month, day, and year of birth;
(iii) Mother's maiden name;
(iv) Sex;
(v) Race;
(vi) Height;
(vii) Weight;
(viii) Color of hair;
(ix) Color of eyes; and
(x) Distinguishing markings, such as scars or
tattoos.
(d) Obtain a
current patient photo.
(e) Request
the patient to voluntarily provide their social security number;
(f) Require the patient to sign an
authorization for disclosure of confidential information, pursuant to
42 C.F.R.
2.34
, for the
limited purpose of authorizing the program to contact each opioid treatment
program within a central registry system and within a radius of one hundred
statute miles to determine if the patient is simultaneously receiving opioid
agonist or partial opioid agonist therapy from another program; and,
(g)
Document in the patient record all information provided and authorizations of
release of information signed pursuant to this rule.
(2) If the program receives the consent in
paragraph (C)(1)(e) of this rule, it shall
is to disclose
to the central registry or any requesting opioid treatment program within two
hundred miles of the program the information provided by the patient in
paragraph (C)(1)(c) of this rule upon:
(a)
Accepting the patient for treatment;
(b) Changing the dosage being administered or
dispensed to the patient; or,
(c) When the treatment is interrupted for a
duration of greater than one week, resumed, or terminated.
(3) If the patient states that they are
currently receiving medication assisted treatment from another program and the
patient is not approved to receive services on a temporary basis before
admitting the patient for treatment, the program shall
is to:
(a) Require the patient to sign an
authorization of disclosure of confidential information, pursuant to
42 C.F.R.
2.34
, for the
limited purpose of authorizing the program to contact the previous program to
notify it that the patient has applied for admission for medication assisted
treatment;
(b) Provide patient
education materials about the transfer process, including but not limited
to, the length of time associated with the
transfer process, responsibilities of the patient, responsibilities of each
agency;
, and
client rights to be re-admitted to the transferring agency if space if
available;
(c) Contact the previous
program by telephone and notify the program that the individual has applied for
admission for medication assisted treatment;
(d) Request information to be transferred
from the previous program to the admitting program within seventy-two hours
that includes medication type; medication dosage; length of time in treatment;
current take home regimen or phase level; and most recent urine drug screen
results;
(e) Request the program to
cease providing medication assisted treatment if it has not already done so,
and only if the admitting program has documentation to verify medication type
and dosage;
(f) Request the
previous program to provide the new program with written documentation (letter
or discharge summary) that it has discharged the patient; and the previous
program shall provide such information within seventy-two hours of receiving
the request. If the previous program states that it has already discharged the
patient, the new program may admit the patient for treatment; and,
(g)
Document the following information in writing in the patient's record:
(i) The name of the program
contacted;
(ii) The date and time
of the contact;
(iii) The name of
the program staff member contacted; and,
(iv) The results of the contact.
(4) If the patient
states that they are a visiting patient approved to receive services on a
temporary basis, before providing medication assisted treatment to the patient
the program shall
is
to:
(a) Contact the other program to
determine that it has not already provided the patient with medication assisted
treatment therapy for the same time period and that it will not do so;
and,
(b) Document the following information in
writing in the patient's medication orders:
(i) The name of the program
contacted;
(ii) The date and time
of the contact;
(iii) The name of
the program staff member contacted; and,
(iv)
The results of the contact.
(5) If the patient states that they are not
currently receiving medication assisted therapy from another program, the
program shall
is
to proceed with patient admission procedures.
(6) When a program determines that it is
providing medication assisted treatment to a patient who is simultaneously
receiving this therapy from one or more other programs, all of the involved
programs shall
are
to immediately:
(a) Confer to determine
which program will accept sole responsibility for the patient;
(b) Revoke the patient's take-home medication
privileges; and,
(c) Notify the state authority by telephone
within seventy-two hours of such determination.
(7) The program which agrees to accept sole
responsibility for a patient with multiple enrollments shall continue to
provide medication assisted treatment. Each of the other programs involved
shall
are to:
(a) Immediately discharge the patient from
the program;
(b) Document in the
patient's record why the patient was discharged from the program;
(c) Provide to the new program, within
seventy-two hours of the discharge, written documentation (letter or discharge
summary) that it has discharged the patient; and,
(d)
Send written notification of the discharge to the state authority within
seventy-two hours of the discharge.
(8) If the state authority determines that
there is patient who is enrolled in multiple programs, and none of the programs
has accepted sole responsibility for the patient, the state authority
shall
is to:
(a) Designate one program which
shall
is to
accept sole responsibility for the patient; and,
(b)
Order the remaining programs to proceed in accordance with paragraph (C)(7) of
this rule.
(D) An opioid treatment program that has
followed the requirements of paragraph (C) of this rule has complied with the
requirement to check for patient dual enrollment, regardless of whether or not
the patient is actually dually enrolled in another program.
Notes
Promulgated Under: 119.03
Statutory Authority: R.C. 5119.37
Rule Amplifies: R.C. 5119.37
Prior Effective Dates: 07/01/2001, 10/01/2003, 06/01/2017, 01/01/2019, 06/11/2021, 06/10/2022
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.